

Revision date: 28-Feb-2013 Version: 1.1 Page 1 of 10

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Cortisporin Otic Suspension (neomycin and polymyxin b sulfates and hydrocortisone otic suspension, usp) Suspension

CORTISPORIN **Trade Name:**

Neomycin and polymyxin b sulfates and hydrocortisone otic suspension, usp suspension Synonyms:

Chemical Family: Not applicable

Intended Use: Pharmaceutical product used as antibiotic agent

2. HAZARDS IDENTIFICATION

Appearance: suspension

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: May be harmful if swallowed. May cause allergic reaction (based on components) Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on

developing fetus (based on components)

EU Indication of danger: Not classified

Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

Page 2 of 10

Material Name: Cortisporin Otic Suspension (neomycin and polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Hydrocortisone acetate	50-03-3	200-004-4	Not Listed	1
Neomycin Sulfate	1405-10-3	215-773-1	Xn;R42/43	0.35
			Repr.Cat.3;R63	
Polymyxin B sulfate	1405-20-5	215-774-7	Xn;R22	0.1
			Xn;R42/43	
Sulfuric acid	7664-93-9	231-639-5	C;R35	**
Propylene glycol	57-55-6	200-338-0	Not Listed	*
Cetyl alcohol	36653-82-4	253-149-0	Not Listed	*
Thimerosal	54-64-8	200-210-4	N; R50/53 R33 T+; R26/27/28	0.01

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: If irritation occurs or persists, get medical attention. Remove clothing and wash affected skin

with soap and water.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Material Name: Cortisporin Otic Suspension (neomycin and polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

During all fire fighting activities, wear appropriate protective equipment, including self-**Fire Fighting Procedures:**

contained breathing apparatus.

Fine particles (such as dust and mists) may fuel fires/explosions. Fire / Explosion Hazards:

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Absorb spills with non-combustible absorbent material and transfer into a labeled container for Measures for Cleaning / Collecting:

disposal.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

Page 3 of 10

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Use adequate ventilation. Avoid contact with eyes, skin and clothing. When handling, use

> appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the

atmosphere should be controlled with dust collectors, HEPA filtration systems or other

equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Neomycin Sulfate

100 µg/m³, Sensitizer Pfizer OEL TWA-8 Hr:

Sulfuric acid

ACGIH Threshold Limit Value (TWA) 0.2 mg/m3 3 mg/m³ **Australia STEL Australia TWA** 1 mg/m³ Austria OEL - MAKs 0.1 mg/m^{3} **Belgium OEL - TWA** 1 mg/m³ 1.0 mg/m³ **Bulgaria OEL - TWA** 0.05 mg/m^3 Cyprus OEL - TWA Czech Republic OEL - TWA 1 mg/m^3 0.05 mg/m³

Denmark OEL - TWA 0.05 mg/m³ Estonia OEL - TWA 0.05 mg/m³ **Finland OEL - TWA** 0.05 mg/m³ 0.05 mg/m³ France OEL - TWA Germany - TRGS 900 - TWAs 0.1 mg/m^{3}

Page 4 of 10

Material Name: Cortisporin Otic Suspension (neomycin and

polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

0.1 mg/m³ Germany (DFG) - MAK **Greece OEL - TWA** 0.05 mg/m³ 0.05 mg/m³ **Hungary OEL - TWA** Ireland OEL - TWAs 1 mg/m^3 1 mg/m^3 Japan - OELs - Ceilings Latvia OEL - TWA 0.05 ma/m³ Lithuania OEL - TWA 0.05 mg/m³ **Luxembourg OEL - TWA** 0.05 mg/m³ Malta OEL - TWA 0.05 mg/m³ **Netherlands OEL - TWA** 0.05 mg/m^3 **OSHA - Final PELS - TWAs:** 1 mg/m^3 **Poland OEL - TWA** 1 mg/m^3 0.05 mg/m³ Portugal OEL - TWA 0.2 mg/m^{3} **Romania OEL - TWA** 0.05 mg/m³ Slovakia OEL - TWA 0.1 mg/m^{3} Slovenia OEL - TWA 0.05 mg/m³ Spain OEL - TWA 0.05 mg/m³ **Sweden OEL - TWAs** 0.1 mg/m^{3}

Propylene glycol

Ireland OEL - TWAs

Australia TWA 150 ppm 474 mg/m³

10 mg/m³ 150 ppm 470 mg/m³

10 mg/m³ Latvia OEL - TWA 7 mg/m³ Lithuania OEL - TWA 7 mg/m^3

Cetyl alcohol

Germany - TRGS 900 - TWAs 20 ppm

200 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Hydrocortisone acetate

Pfizer Occupational Exposure OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Band (OEB):

Polymyxin B sulfate

Pfizer Occupational Exposure OEB 2 - Sensitizer (control exposure to the range of 100ug/m³ to < 1000ug/m³, provide

additional precautions to protect from skin contact) Band (OEB):

Engineering Controls: General room ventilation is adequate unless the process generates dust, mist or fumes. Local

and general ventilation should be used as necessary, when handling this material in bulk.

Refer to specific Member State legislation for requirements under Community environmental **Environmental Exposure Controls:**

legislation.

Material Name: Cortisporin Otic Suspension (neomycin and Page 5 of 10

polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Suspension Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Polymyxin B sulfate

Mouse Oral LD50 790 mg/kg Rat SC LD50 50 mg/kg Rat IV LD50 3.98 mg/kg

Hydrocortisone acetate

Mouse IP LD50 2300 mg/kg Rat SC LD50 449 mg/kg

Thimerosal

Rat Oral LD50 75 mg/kg Mouse Oral LD50 91 mg/kg Rat Subcutaneous LD50 98 mg/kg

Polysorbate 80

Material Name: Cortisporin Otic Suspension (neomycin and

polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 25 g/kg

Neomycin Sulfate

Rat Oral LD 50 2750 mg/kg

Mouse Oral LD 50 2880 mg/kg

Mouse Intraperitoneal LD 50 116 mg/kg

Rat Subcutaneous LD 50 633 mg/kg

Mouse Subcutaneous LD 50 275 mg/kg

Sulfuric acid

Rat Oral LD50 2140 mg/kg

Cetyl alcohol

Rat Oral LD50 5000 mg/kg Rabbit Dermal LD50 > 2,600 mg/kg Mouse Oral LD50 3200 mg/kg

Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Page 6 of 10

Irritation / Sensitization: (Study Type, Species, Severity)

Thimerosal

Eye Irritation Rabbit Mild

Neomycin Sulfate

Skin Irritation Rabbit Moderate Eye Irritation Rabbit Minimal

Sulfuric acid

Eye Irritation Rabbit Severe

Propylene glycol

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Polymyxin B sulfate

9 Day(s) Mouse Subcutaneous 284 mg/kg LOAEL Skin

Neomycin Sulfate

6 Week(s) Dog Oral 100 mg/kg/day NOAEL No effects at maximum dose

3 Month(s) Guinea Pig Oral 10 mg/kg/day NOAEL No effects at maximum dose

3 Month(s) Dog Subcutaneous 20 mg/kg/day LOAEL Kidney 12 Month(s) Cat Oral 12 mg/kg/day NOAEL Blood forming organs

3 Month(s) Guinea Pig Subcutaneous 10 mg/kg/day LOAEL Kidney

PZ02102

Page 7 of 10

Material Name: Cortisporin Otic Suspension (neomycin and

polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Neomycin Sulfate

Reproductive & Fertility Mouse 4000 mg/L **NOAEL** No effects at maximum dose Oral 2 Generation Reproductive Toxicity Rat Oral 25 mg/kg/day NOAEL Fetotoxicity Reproductive & Fertility Rat Oral 25 mg/kg/day NOAEL No effects at maximum dose

Prenatal & Postnatal Development Subcutaneous 6 mg/kg/day LOAEL Developmental toxicity Rat

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Neomycin Sulfate

Bacterial Mutagenicity (Ames) Salmonella , E. coli Negative

Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative

In Vivo Cytogenetics Negative Mouse

In Vitro Chromosome Aberration **Human Lymphocytes** Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Neomycin Sulfate

2 Year(s) Rat Oral 25 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components present in this material at concentrations equal to or greater than

0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

Sulfuric acid

IARC: Group 1 (Carcinogenic to Humans)

Listed OSHA:

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to

the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Neomycin Sulfate

Daphnia magna (Water Flea) OECD EC50 48 Hours 68 mg/L Salmo gairdneri (Trout) OECD NOEC 96 Hours >1000 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Neomycin Sulfate

Activated sludge OECD EC50 399 mg/L 3 Hours

Material Name: Cortisporin Otic Suspension (neomycin and polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. This product contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP).

Page 8 of 10

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Not classified **EU Indication of danger:** Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Hydrocortisone acetate

Australia (AICS):PresentStandard for the Uniform SchedulingSchedule 2for Drugs and Poisons:Schedule 3EU EINECS/ELINCS List200-004-4

Neomycin Sulfate

California Proposition 65 developmental toxicity initial date 10/1/92

Inventory - United States TSCA - Sect. 8(b) Present

Page 9 of 10

Material Name: Cortisporin Otic Suspension (neomycin and

polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

15. REGULATORY INFORMATION	
Australia (AICS):	Present
EU EINECS/ELINCS List	215-773-1
LO LINEOS/LLINOS LIST	210 770 1
Polymyxin B sulfate	
Australia (AICS):	Present
EU EINECS/ELINCS List	215-774-7
Polysorbate 80	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
, ,	
Sulfuric acid	
CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances	1000 lb
and their Reportable Quantities:	454 kg
CERCLA/SARA - Section 302 Extremely Hazardous	1000 lb
TPQs	
CERCLA/SARA - Section 302 Extremely Hazardous	1000 lb
Substances EPCRA RQs	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 6
for Drugs and Poisons:	
EU EINECS/ELINCS List	231-639-5
Propylene glycol	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-338-0
Ontal also had	
Cetyl alcohol	Present
Inventory - United States TSCA - Sect. 8(b)	
Australia (AICS):	Present
EU EINECS/ELINCS List	253-149-0
Thimerosal	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-210-4
EU EINECS/ELINCS LIST	200-210-4
Water for injection	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	231-791-2
= 3 = = 30, =	

Additional Information:

White petrolatum is not classified as a carcinogen. Nota N applies since the full refining history is known and it can be shown that the substances from which the petroleum jelly was produced are not a carcinogen.

Page 10 of 10

Material Name: Cortisporin Otic Suspension (neomycin and polymyxin b sulfates and hydrocortisone otic suspension,

usp) Suspension

Revision date: 28-Feb-2013 Version: 1.1

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R63 - Possible risk of harm to the unborn child.

R35 - Causes severe burns.

R33 - Danger of cumulative effects.

R42/43 - May cause sensitization by inhalation and skin contact.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 11 - Toxicology Information.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
